Latest Content

A narrative review links IL-17 signaling to metabolic syndrome and cardiovascular risk in psoriasis, though hard-outcome trial data remain limited.

After CAR T-cell therapy relapse in mantle cell lymphoma, an antibody drug conjugate regimen adapted from DLBCL shows durable remission.

Employers with complete claims data access deploy more cost-containment strategies as health care costs rise and employers seek greater PBM transparency.

Taking effect in October 2026, the final rule will end federal Medicaid and CHIP funding for gender-affirming care for transgender minors.

A new international platform trial groups rare pediatric sarcoma substudies under 1 protocol to speed drug access and data collection.

Trump's vaccine executive order calls for fewer routine childhood vaccines and changes to MMR, raising questions about coverage, access, and vaccine uptake.

Most Medicare beneficiaries with ATTR-CM waited more than 6 months for diagnosis after heart failure onset, with longer delays among women.

HHS announced proposed FDA changes to GRAS oversight and a proposed definition of ultra-processed foods as part of the MAHA agenda.

The BTK inhibitor also showed fewer severe adverse events and better patient-reported quality of life than chemoimmunotherapy.